Bacterial and fungal cell membranes and proteins

Bacterial and fungal cell membranes and proteins represent a broad class of therapeutic targets essential for the survival and replication of pathogenic microorganisms. In bacteria, the cell envelope—comprising the peptidoglycan cell wall and the cytoplasmic membrane—provides structural integrity and regulates transport, while ribosomes facilitate vital protein synthesis [1][2]. Fungal targets are distinct, often focusing on the cell wall's chitin and glucan components or the unique sterol, ergosterol, within the plasma membrane [3]. Antimicrobial and antifungal drugs exploit the biochemical differences between these microbial structures and human host cells to achieve selective toxicity [2]. For instance, beta-lactams inhibit bacterial cell wall synthesis, while polyenes bind to fungal ergosterol to create lethal pores [3][4]. Despite their clinical utility, targeting these structures faces significant challenges, most notably the rapid emergence of antimicrobial resistance (AMR) [5]. Additionally, some agents targeting these structures can cause host toxicity, such as the nephrotoxicity associated with polymyxins or amphotericin B [4][6]. This target category is fundamental to the treatment of infectious diseases but requires specific focus on individual molecular components for drug design.

Other names

Microbial cell envelope componentsProkaryotic and fungal cell targetsBacterial and fungal structural proteins

Inhibition of peptidoglycan synthesis, disruption of membrane lipid bilayers, binding to ergosterol to form pores, inhibition of 30S or 50S ribosomal subunits, and inhibition of beta-glucan synthesis [2][3][4].